{
  "docId": "019dd923-5f69-752d-a9b9-7febd653c093",
  "docSlug": "ZFP1QxeNpCfFhbrzYAWi",
  "documentTitle": "See the 18-slide pitch deck a genetics startup used to raise $100 million and explore the 'dark side' of the genome",
  "authorId": "Pitchdecks",
  "authorName": "CAMP4",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 15,
  "pageCount": 18,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 16,
  "notes": "N=3, dose day 1,14; sacrifice day 21. Safety data indicates >25X therapeutic margin.",
  "elementsJson": [
    "action_title",
    "bar_chart_grouped",
    "callout_box"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5f69-752d-a9b9-7febd653c093/15",
  "deckHref": "/decks/019dd923-5f69-752d-a9b9-7febd653c093",
  "deckJsonHref": "/decks/019dd923-5f69-752d-a9b9-7febd653c093.json",
  "deckAnchorHref": "/decks/019dd923-5f69-752d-a9b9-7febd653c093#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.68,
        "y": 0.34
      },
      "kind": "callout",
      "text": "No adverse clinical or histological findings up to 5 mg. Supports >25X therapeutic margin for CMP-SCN-001",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0dfff3af-18fd-45d5-b4ec-7bae22591ca8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.58,
        "x": 0.06,
        "y": 0.34
      },
      "kind": "chart",
      "text": "SCN1A protein upregulation across brain regions",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d7fd18bd-8997-4b78-b147-a215712ea17a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.1,
        "x": 0.52,
        "y": 0.25
      },
      "kind": "legend",
      "text": "PBS vs 0.2mg CMP-SCN",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8b5e8dd8-97c8-4e1c-a56c-148396947f69",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "therapeutic margin: >25X",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-abe4-75dc-a304-2910790811ba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.675,
        "y": 0.84
      },
      "kind": "paragraph",
      "text": "N=3, dose day 1,14; sacrifice day 21",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "db620df9-20bc-406f-969f-6244b3ef95ac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.96,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "CMP-SCN-001 upregulates SCN1A protein across different relevant brain regions in non-human primates at low efficacious dose",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62d5297f-5332-4ac8-a90c-62206ffa2177",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 18,
      "from": 13,
      "beatId": "83232633-6fc0-4a1b-a0a5-fe516b3d8578",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The deck presents CAMP4's approach to Dravet and the potential solution offered by their RAP (p13-18)",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 16,
      "from": 12,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "ad824c9f-ade3-46dc-85b3-9835f23c9a9a",
      "evidence": "The deck presents the market opportunity for CAMP4's targeted SCN1A upregulation approach (p16)",
      "position": 0,
      "objective": "Highlight the cost of inaction for Dravet Syndrome patients",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}